Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-12-2012 | Article

Identification, molecular characterisation and antimicrobial susceptibility of genomovars of the Burkholderia cepacia complex in Spain

Authors: M. J. Medina-Pascual, S. Valdezate, P. Villalón, N. Garrido, V. Rubio, J. A. Saéz-Nieto

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2012

Abstract

Burkholderia spp. strains collected in Spain over a 13-year period from patients with cystic fibrosis (CF) (n = 148), non-CF patients (n = 103) and from environmental sources (n = 64) were characterised. One hundred and forty-one of the examined strains were involved in seven suspected nosocomial disease outbreaks. Strains were identified by their 16s rRNA and recA genes. Their genetic relatedness, the possession of cable pili and the B. cepacia epidemic strain marker (BCESM), and their susceptibility to antimicrobial agents were studied using pulsed-field gel electrophoresis (PFGE), cblA and esmR genes analysis, and by the E-test, respectively. The genomovar distribution for the 315 strains was as follows: B. stabilis 29.5 %, B. cepacia 14.9 %, B. multivorans 11.1 %, B. cenocepacia IIIA 9.5 %, B. vietnamiensis 3.8 %, B. cenocepacia IIIB 3.5 %, and B. ambifaria and B. pyrrocinia 0.3 % each. The genetic diversity of the B. cepacia complex (Bcc) was ample, with 57 different SpeI types, showing a genetic similarity of 36.4–96.6 %. No strain carried cblA, whereas 25 B. cenocepacia genotypes harboured BCESM (23 from patients with CF). Antimicrobial resistance rates to tobramycin (TOB; 86 %) and imipenem (IPM; 67 %) were high. The strains from patients with CF showed significantly greater resistance to piperacillin (PIP), levofloxacin (LVX) and co-trimoxazole (SXT) than those isolated from non-CF patients (p < 0.05). In conclusion, B. cenocepacia was the most prevalent genomovar found in patients with CF (19.1 %), whereas B. cepacia was the most common among non-CF patients (20.7 %). B. stabilis (47.6 %) was the most common environmental genomovar. Susceptibility to antimicrobial agents depended on genomovar status and strain origin.

Available only for authorised users

Vandamme P, Holmes B, Vancanneyt M, Coenye T, Hoste B, Coopman R, Revets H, Lauwers S, Gillis M, Kersters K, Govan JRW (1997) Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 47:1188–1200PubMedCrossRef

Vandamme P, Holmes B, Coenye T, Goris J, Mahenthiralingam E, Lipuma JJ, Govan JRW (2003) Burkholderia cenocepacia sp. nov.—a new twist to an old story. Res Microbiol 154:91–96PubMedCrossRef

Vandamme P, Mahenthiralingam E, Holmes B, Coenye T, Hoste B, De Vos P, Henry D, Speert DP (2000) Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV). J Clin Microbiol 38:1042–1047PubMed

Gillis M, Van Van T, Bardin R, Goor M, Hebbar P, Willems A, Segers P, Kersters K, Heulin T, Fernandez MP (1995) Polyphasic taxonomy in the genus Burkholderia leading to an emended description of the genus and proposition of Burkholderia vietnamiensis sp. nov. for N₂-fixing isolates from rice in Vietnam. Int J Syst Bacteriol 45:274–289CrossRef

Vermis K, Coenye T, Lipuma JJ, Mahenthiralingam E, Nelis HJ, Vandamme P (2004) Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int J Syst Evol Microbiol 54:689–691PubMedCrossRef

Coenye T, Mahenthiralingam E, Henry D, LiPuma JJ, Laevens S, Gillis M, Speert DP, Vandamme P (2001) Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. Int J Syst Evol Microbiol 51:1481–1490PubMedCrossRef

Vandamme P, Henry D, Coenye T, Nzula S, Vancanneyt M, Lipuma JJ, Speert DP, Govan JRW, Mahenthiralingam E (2002) Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunol Med Microbiol 33:143–149PubMedCrossRef

Yabuuchi E, Kawamura Y, Ezaki T, Ikedo M, Dejsirilert S, Fujiwara N, Naka T, Kobayashi K (2000) Burkholderia uboniae sp. nov., L-arabinose-assimilating but different from Burkholderia thailandensis and Burkholderia vietnamiensis. Microbiol Immunol 44:307–317PubMed

Vermis K, Coenye T, Mahenthiralingam E, Nelis HJ, Vandamme P (2002) Evaluation of species-specific recA-based PCR tests for genomovar level identification within the Burkholderia cepacia complex. J Med Microbiol 51:937–940PubMed

10.

Vanlaere E, Lipuma JJ, Baldwin A, Henry D, De Brandt E, Mahenthiralingam E, Speert D, Dowson C, Vandamme P (2008) Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int J Syst Evol Microbiol 58:1580–1590PubMedCrossRef

11.

Vanlaere E, Baldwin A, Gevers D, Henry D, De Brandt E, Lipuma JJ, Mahenthiralingam E, Speert DP, Dowson C, Vandamme P (2009) Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. Int J Syst Evol Microbiol 59:102–111PubMedCrossRef

12.

Gilligan PH (1991) Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4:35–51PubMed

13.

Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, Ochs H, Quie P, Buckley RH, Foster CB, Chanock SJ, Dickler H (2000) Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 79:155–169CrossRef

14.

Clode FE, Kaufmann ME, Malnick H, Pitt TL (2000) Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom. J Clin Microbiol 38:1763–1766PubMed

15.

Gilligan PH, Lum G, Vandamme AR, Whittier S (2003) Burkholderia, Stenotrophomonas, Ralstonia, Brevundimonas, Comamonas, Delftia, Pandoraea, and Acidovorax. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (eds) Manual of clinical microbiology, 8th edn. ASM Press, Washington, DC, pp 729–748

16.

Mahenthiralingam E, Urban TA, Goldberg JB (2005) The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 3:144–156PubMedCrossRef

17.

Nzula S, Vandamme P, Govan JRW (2002) Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J Antimicrob Chemother 50:265–269PubMedCrossRef

18.

Weisburg WG, Barns SM, Pelletier DA, Lane DJ (1991) 16S ribosomal DNA amplification for phylogenetic study. J Bacteriol 173:697–703PubMed

19.

Mahenthiralingam E, Bischof J, Byrne SK, Radomski C, Davies JE, Av-Gay Y, Vandamme P (2000) DNA-based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J Clin Microbiol 38:3165–3173PubMed

20.

Valdezate S, Vindel A, Maiz L, Baquero F, Escobar H, Cantón R (2001) Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991–1998. Emerg Infect Dis 7:113–122PubMedCrossRef

21.

Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239PubMed

22.

National Committee for Clinical Laboratory Standards (NCCLS) (2007) Performance standards for antimicrobial susceptibility testing; Seventeenth Informational Supplement. M100-S17. NCCLS, Wayne, PA

23.

Drancourt M, Bollet C, Carlioz A, Martelin R, Gayral JP, Raoult D (2000) 16S ribosomal DNA sequence analysis of a large collection of environmental and clinical unidentifiable bacterial isolates. J Clin Microbiol 38:3623–3630PubMed

24.

Molina-Cabrillana J, Bolaños-Rivero M, Alvarez-León EE, Martín Sánchez AM, Sánchez-Palacios M, Alvarez D, Sáez-Nieto JA (2006) Intrinsically contaminated alcohol-free mouthwash implicated in a nosocomial outbreak of Burkholderia cepacia colonization and infection. Infect Control Hosp Epidemiol 27:1281–1282PubMedCrossRef

25.

Bernhardt SA, Spilker T, Coffey T, LiPuma JJ (2003) Burkholderia cepacia complex in cystic fibrosis: frequency of strain replacement during chronic infection. Clin Infect Dis 37:780–785PubMedCrossRef

26.

McDowell A, Mahenthiralingam E, Dunbar KEA, Moore JE, Crowe M, Elborn JS (2004) Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation. J Med Microbiol 53:663–668PubMedCrossRef

27.

Mahenthiralingam E, Baldwin A, Dowson CG (2008) Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology. J Appl Microbiol 104:1539–1551PubMedCrossRef

28.

Heath DG, Hohneker K, Carriker C, Smith K, Routh J, LiPuma JJ, Aris RM, Weber D, Gilligan PH (2002) Six-year molecular analysis of Burkholderia cepacia complex isolates among cystic fibrosis patients at a referral center for lung transplantation. J Clin Microbiol 40:1188–1193PubMedCrossRef

29.

Golini G, Cazzola G, Fontana R (2006) Molecular epidemiology and antibiotic susceptibility of Burkholderia cepacia-complex isolates from an Italian cystic fibrosis centre. Eur J Clin Microbiol Infect Dis 25:175–180PubMedCrossRef

30.

Allice T, Scutera S, Chirillo MG, Savoia D (2006) Burkholderia respiratory tract infections in Italian patients with cystic fibrosis: molecular characterization. J Infect 53:159–165PubMedCrossRef

31.

Saiman L, Siegel J (2004) Infection control in cystic fibrosis. Clin Microbiol Rev 17:57–71PubMedCrossRef

32.

Valderrey AD, Pozuelo MJ, Jiménez PA, Maciá MD, Oliver A, Rotger R (2010) Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Diagn Microbiol Infect Dis 68:20–27PubMedCrossRef

33.

Kutty PK, Moody B, Gullion JS, Zervos M, Ajluni M, Washburn R, Sanderson R, Kainer MA, Powell TA, Clarke CF, Powell RJ, Pascoe N, Shams A, Lipuma JJ, Jensen B, Noble-Wang J, Arduino MJ, McDonald LC (2007) Multistate outbreak of Burkholderia cenocepacia colonization and infection associated with the use of intrinsically contaminated alcohol-free mouthwash. Chest 132:1825–1831PubMedCrossRef

34.

Nasser RM, Rahi AC, Haddad MF, Daoud Z, Irani-Hakime N, Almawi WY (2004) Outbreak of Burkholderia cepacia bacteremia traced to contaminated hospital water used for dilution of an alcohol skin antiseptic. Infect Control Hosp Epidemiol 25:231–239PubMedCrossRef

35.

Souza AV, Moreira CR, Pasternak J, Hirata Mde L, Saltini DA, Caetano VC, Ciosak S, Azevedo FM, Severino P, Vandamme P, Magalhães VD (2004) Characterizing uncommon Burkholderia cepacia complex isolates from an outbreak in a haemodialysis unit. J Med Microbiol 53:999–1005PubMedCrossRef

36.

Graindorge A, Menard A, Neto M, Bouvet C, Miollan R, Gaillard S, de Montclos H, Laurent F, Cournoyer B (2010) Epidemiology and molecular characterization of a clone of Burkholderia cenocepacia responsible for nosocomial pulmonary tract infections in a French intensive care unit. Diagn Microbiol Infect Dis 66:29–40PubMedCrossRef

37.

Jacobson M, Wray R, Kovach D, Henry D, Speert D, Matlow A (2006) Sustained endemicity of Burkholderia cepacia complex in a pediatric institution, associated with contaminated ultrasound gel. Infect Control Hosp Epidemiol 27:362–366PubMedCrossRef

38.

Messi P, Guerrieri E, Bondi M (2005) Antibiotic resistance and antibacterial activity in heterotrophic bacteria of mineral water origin. Sci Total Environ 346:213–219PubMedCrossRef

39.

Oie S, Matsuzaka Y, Kiyonaga H, Maeda K, Kamiya A (2008) Microbiological safety of bottled mineral water in patients susceptible to infections. Shokuhin Eiseigaku Zasshi 49:308–310PubMedCrossRef

40.

Jassem AN, Zlosnik JEA, Henry DA, Hancock REW, Ernst RK, Speert DP (2011) In vitro susceptibility of Burkholderia vietnamiensis to aminoglycosides. Antimicrob Agents Chemother 55:2256–2264PubMedCrossRef

41.

Vermis K, Vandamme PA, Nelis HJ (2003) Burkholderia cepacia complex genomovars: utilization of carbon sources, susceptibility to antimicrobial agents and growth on selective media. J Appl Microbiol 95:1191–1199PubMedCrossRef

42.

Bevivino A, Dalmastri C, Tabacchioni S, Chiarini L, Belli ML, Piana S, Materazzo A, Vandamme P, Manno G (2002) Burkholderia cepacia complex bacteria from clinical and environmental sources in Italy: genomovar status and distribution of traits related to virulence and transmissibility. J Clin Microbiol 40:846–851PubMedCrossRef

Title: Identification, molecular characterisation and antimicrobial susceptibility of genomovars of the Burkholderia cepacia complex in Spain
Authors: M. J. Medina-Pascual
S. Valdezate
P. Villalón
N. Garrido
V. Rubio
J. A. Saéz-Nieto
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2012
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-012-1707-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2012

Membrane-damaging potential of natural L-(−)-usnic acid in Staphylococcus aureus

Serum apoptosis markers in HIV-infected patients with human herpesvirus type 8 and herpes simplex virus type 2 co-infection

Diversity in the antimicrobial susceptibility patterns of methicillin-resistant Staphylococcus aureus clones

Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus

Cefazolin plasma protein binding and its covariates in neonates

Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials